 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 GLOBE NEWSWIRE -- Denali Therapeutics Inc. NASDAQ: DNLI, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier BBB for neurodegenerative diseases, today announced additional positive interim results from the ongoing Phase 12 study evaluating ETV:IDS DNL310 as a potential brain-penetrant enzyme replacement therapy for treating both central nervous system CNS and peripheral manifestations of Hunter syndrome MPS II. The data will be presented later today during a late-breaker session at WORLDSymposiumTM. Denali management will host an analyst webinar today beginning at 8:00 a.m. Eastern Time to discuss both interim clinical and new preclinical data that will be presented at the conference. 